Brandywine Managers LLC acquired a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 14,588 shares of the medical research company's stock, valued at approximately $3,960,000. Natera comprises about 2.0% of Brandywine Managers LLC's investment portfolio, making the stock its 5th largest holding.
Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. BlackRock Inc. bought a new position in Natera in the second quarter valued at about $2,962,770,000. Wellington Management Group LLP raised its position in Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. State Street Corp boosted its stake in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock valued at $545,624,000 after purchasing an additional 72,087 shares in the last quarter. Finally, Coatue Management LLC boosted its stake in shares of Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock valued at $603,270,000 after purchasing an additional 2,463,008 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.
Insider Transactions at Natera
In other news, Director Gail Boxer Marcus sold 11,000 shares of the company's stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the sale, the director directly owned 6,183 shares of the company's stock, valued at approximately $1,343,009.43. This represents a 64.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Roelof Botha sold 78,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the sale, the director owned 1,076,198 shares of the company's stock, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 177,955 shares of company stock worth $40,704,193. Company insiders own 5.05% of the company's stock.
Natera Price Performance
Shares of NTRA opened at $327.72 on Tuesday. Natera, Inc. has a 1 year low of $157.43 and a 1 year high of $333.56. The company has a market capitalization of $47.24 billion, a price-to-earnings ratio of -240.97 and a beta of 1.51. The business has a 50-day moving average of $276.45 and a 200-day moving average of $230.09.
Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analysts' expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm's revenue was up 37.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.74) earnings per share. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.02 EPS for the current year.
Analyst Ratings Changes
NTRA has been the subject of several recent research reports. Leerink Partners set a $330.00 price objective on Natera in a research note on Friday, August 7th. Wells Fargo & Company lifted their target price on shares of Natera from $220.00 to $284.00 and gave the stock an "equal weight" rating in a research report on Friday, August 7th. BTIG Research boosted their target price on shares of Natera from $290.00 to $320.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Sanford C. Bernstein began coverage on shares of Natera in a research report on Friday, June 26th. They issued an "outperform" rating and a $310.00 price target for the company. Finally, Citigroup raised their price target on shares of Natera from $315.00 to $365.00 and gave the company a "buy" rating in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $319.38.
Check Out Our Latest Stock Analysis on NTRA
About Natera
(
Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
See Also
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
